<!DOCTYPE html>
<html lang="en" dir="ltr">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Hemophilia Hub | CarePedia Information Center</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Rubik:wght@300;400;500;600;700;800;900&display=swap" rel="stylesheet">
<link rel="alternate" hreflang="he" href="https://carepedia.org/hemophilia" />
<link rel="alternate" hreflang="en" href="https://carepedia.org/en/hemophilia" />

<style>
* { margin: 0; padding: 0; box-sizing: border-box; }

:root {
  --primary: #0f4c75;
  --primary-light: #3282b8;
  --accent: #00b894;
  --accent-light: #55efc4;
  --warm: #fdcb6e;
  --warm-dark: #e17055;
  --bg: #f0f4f8;
  --card: #ffffff;
  --text: #2c3e50;
  --text-light: #5d6d7e;
  --shadow: 0 4px 20px rgba(0,0,0,0.08);
  --shadow-hover: 0 12px 40px rgba(0,0,0,0.18);
  --radius: 16px;
  --transition: all 0.3s cubic-bezier(.4,0,.2,1);
  /* Aliases for Iconify icons */
  --forest: #0f4c75;
  --forest-mid: #3282b8;
  --forest-light: rgba(50,130,184,0.12);
  --amber: #fdcb6e;
  --amber-light: rgba(253,203,110,0.12);
  --border: #dde4eb;
}

body {
  font-family: 'Rubik', 'Segoe UI', Tahoma, Arial, sans-serif;
  background: var(--bg);
  color: var(--text);
  line-height: 1.8;
  overflow-x: hidden;
  position: relative;
}

body::before {
  content: '';
  position: fixed;
  top: 0; left: 0; width: 100vw; height: 100vh;
  background:
    radial-gradient(ellipse at 10% 20%, rgba(15,76,117,0.07) 0%, transparent 50%),
    radial-gradient(ellipse at 90% 80%, rgba(0,184,148,0.07) 0%, transparent 50%),
    radial-gradient(ellipse at 50% 50%, rgba(253,203,110,0.05) 0%, transparent 60%);
  pointer-events: none;
  z-index: 0;
}

.scroll-progress {
  position: fixed;
  top: 0; right: 0;
  width: 100%; height: 4px;
  z-index: 2000;
  background: transparent;
}
.scroll-progress .bar {
  height: 100%; width: 0%;
  background: linear-gradient(90deg, var(--accent), var(--primary-light), var(--warm));
  border-radius: 0 0 0 4px;
  transition: width 0.1s linear;
}

.sidebar {
  position: fixed;
  top: 0; left: 0;
  width: 280px; height: 100vh;
  background: rgba(15,76,117,0.85);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border-right: 1px solid rgba(255,255,255,0.1);
  z-index: 1000;
  padding: 30px 20px;
  overflow-y: auto;
  transition: transform 0.4s cubic-bezier(.4,0,.2,1);
}
.sidebar .logo {
  text-align: center;
  margin-bottom: 30px;
  padding-bottom: 20px;
  border-bottom: 1px solid rgba(255,255,255,0.15);
}
.sidebar .logo .icon { font-size: 48px; }
.sidebar .logo h2 { color: #fff; font-size: 18px; margin-top: 8px; font-weight: 600; }
.sidebar nav a {
  display: flex; align-items: center; gap: 12px;
  padding: 14px 18px; color: rgba(255,255,255,0.8);
  text-decoration: none; border-radius: 12px;
  margin-bottom: 4px; font-size: 15px; transition: var(--transition);
}
.sidebar nav a:hover, .sidebar nav a.active {
  background: rgba(255,255,255,0.15); color: #fff; transform: translateX(4px);
}
.sidebar nav a .nav-icon { font-size: 22px; min-width: 30px; text-align: center; }

.menu-toggle {
  display: none;
  position: fixed;
  top: 20px; left: 20px;
  z-index: 1100;
  background: var(--primary); color: #fff;
  border: none; border-radius: 12px;
  width: 50px; height: 50px; font-size: 24px;
  cursor: pointer; box-shadow: var(--shadow); transition: var(--transition);
}
.menu-toggle:hover { transform: scale(1.05); }
.menu-toggle.open { border-radius: 50%; background: var(--warm-dark); }

.main {
  margin-left: 280px;
  min-height: 100vh;
  position: relative;
  z-index: 1;
}

.hero {
  background: linear-gradient(135deg, var(--primary) 0%, #3282b8 40%, var(--accent) 100%);
  padding: 80px 60px;
  color: #fff;
  position: relative;
  overflow: hidden;
}
.hero::before {
  content: '';
  position: absolute;
  top: -50%; left: -50%;
  width: 200%; height: 200%;
  background: radial-gradient(circle, rgba(255,255,255,0.05) 0%, transparent 60%);
  animation: float 20s linear infinite;
}
@keyframes float { 0% { transform: rotate(0deg); } 100% { transform: rotate(360deg); } }
.hero-content { position: relative; z-index: 1; max-width: 900px; }
.hero h1 { font-size: 52px; font-weight: 800; margin-bottom: 10px; line-height: 1.3; }
.hero .greeting { font-size: 22px; opacity: 0.95; margin-bottom: 30px; line-height: 1.7; }
.hero .subtitle { font-size: 18px; opacity: 0.8; max-width: 700px; }

.fade-in { opacity: 0; transform: translateY(30px); transition: opacity 0.7s ease, transform 0.7s ease; }
.fade-in.visible { opacity: 1; transform: translateY(0); }

.section { padding: 60px; max-width: 1100px; margin: 0 auto; }
.section-header {
  display: flex; align-items: center; gap: 16px;
  margin-bottom: 40px; padding-bottom: 20px;
  border-bottom: 3px solid var(--primary-light);
}
.section-header .sec-icon { font-size: 42px; }
.section-header h2 { font-size: 36px; color: var(--primary); }
.section-header p { color: var(--text-light); font-size: 16px; margin-top: 4px; }

.cards-grid {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
  gap: 24px; margin-bottom: 40px;
}
.card {
  background: var(--card); border-radius: var(--radius); padding: 30px;
  box-shadow: var(--shadow); transition: var(--transition);
  border-top: 4px solid var(--primary-light);
  position: relative; overflow: hidden;
}
.card:hover { transform: translateY(-6px) scale(1.01); box-shadow: var(--shadow-hover); }
.card .card-icon { font-size: 40px; margin-bottom: 16px; }
.card h3 { font-size: 20px; color: var(--primary); margin-bottom: 12px; }
.card p { color: var(--text-light); font-size: 15px; line-height: 1.8; }
.card.green { border-top-color: var(--accent); }
.card.orange { border-top-color: var(--warm); }
.card.blue { border-top-color: var(--primary-light); }

.cat-grid {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(240px, 1fr));
  gap: 20px; margin-top: 40px;
}
.cat-card {
  background: var(--card); border-radius: var(--radius); padding: 30px 24px;
  text-align: center; cursor: pointer; transition: var(--transition);
  box-shadow: var(--shadow); text-decoration: none; color: var(--text);
}
.cat-card:hover { transform: translateY(-6px) scale(1.02); box-shadow: var(--shadow-hover); }
.cat-card .cat-icon { font-size: 48px; margin-bottom: 14px; }
.cat-card h3 { font-size: 18px; color: var(--primary); margin-bottom: 8px; }
.cat-card p { font-size: 13px; color: var(--text-light); }

.accordion { margin-bottom: 16px; }
.accordion-header {
  background: var(--card); padding: 20px 24px; border-radius: var(--radius);
  cursor: pointer; display: flex; justify-content: space-between; align-items: center;
  box-shadow: var(--shadow); transition: var(--transition);
  font-size: 17px; font-weight: 600; color: var(--primary);
}
.accordion-header:hover { background: #eef4fb; }
.accordion-header .arrow { transition: transform 0.3s ease; font-size: 20px; }
.accordion-header.open .arrow { transform: rotate(180deg); }
.accordion-body {
  max-height: 0; overflow: clip; transition: max-height 0.4s ease;
  background: var(--card); border-radius: 0 0 var(--radius) var(--radius); margin-top: -8px;
}
.accordion-body .inner { padding: 20px 24px 24px; color: var(--text-light); line-height: 2; }

.tabs { display: flex; gap: 8px; margin-bottom: 24px; flex-wrap: wrap; }
.tab-btn {
  padding: 12px 24px; background: var(--card);
  border: 2px solid #dde4eb; border-radius: 30px;
  cursor: pointer; font-size: 15px; font-family: inherit;
  color: var(--text-light); transition: var(--transition);
}
.tab-btn:hover { border-color: var(--primary-light); color: var(--primary); }
.tab-btn.active { background: var(--primary); color: #fff; border-color: var(--primary); }
.tab-content { display: none; animation: fadeIn 0.4s ease; }
.tab-content.active { display: block; }
@keyframes fadeIn { from { opacity: 0; transform: translateY(10px); } to { opacity: 1; transform: translateY(0); } }

.info-box {
  background: linear-gradient(135deg, #eaf4fb 0%, #e8f8f0 100%);
  border-radius: var(--radius); padding: 24px 28px; margin: 24px 0;
  border-left: 5px solid var(--primary-light);
}
.info-box.warning { background: linear-gradient(135deg, #fef9e7 0%, #fdebd0 100%); border-left-color: var(--warm); }
.info-box.success { background: linear-gradient(135deg, #e8f8f0 0%, #d5f5e3 100%); border-left-color: var(--accent); }
.info-box h4 { color: var(--primary); margin-bottom: 8px; font-size: 17px; }
.info-box p { color: var(--text-light); font-size: 15px; }

.link-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 12px 24px; background: var(--primary);
  color: #fff; text-decoration: none; border-radius: 30px;
  font-size: 15px; transition: var(--transition); margin: 6px;
}
.link-btn:hover { background: var(--primary-light); transform: translateY(-2px); }
.link-btn.green { background: var(--accent); }
.link-btn.green:hover { background: var(--accent-light); color: var(--text); }
.link-btn.orange { background: var(--warm-dark); }
.link-btn.orange:hover { background: var(--warm); color: var(--text); }

.styled-table {
  width: 100%; border-collapse: collapse; margin: 20px 0;
  background: var(--card); border-radius: var(--radius);
  overflow: hidden; box-shadow: var(--shadow);
}
.styled-table thead { background: var(--primary); color: #fff; }
.styled-table th { padding: 16px 20px; text-align: left; font-weight: 600; }
.styled-table td { padding: 14px 20px; border-bottom: 1px solid #eee; }
.styled-table tbody tr:hover { background: #f7fafc; }

.timeline { position: relative; padding-left: 40px; margin: 30px 0; }
.timeline::before {
  content: '';
  position: absolute; left: 12px; top: 0; bottom: 0;
  width: 3px;
  background: linear-gradient(to bottom, var(--primary-light), var(--accent));
  border-radius: 3px;
}
.timeline-item {
  position: relative; margin-bottom: 30px; padding: 24px;
  background: var(--card); border-radius: var(--radius); box-shadow: var(--shadow);
}
.timeline-item::before {
  content: ''; position: absolute;
  left: -34px; top: 30px;
  width: 16px; height: 16px;
  background: var(--accent); border-radius: 50%; border: 3px solid var(--bg);
}
.timeline-item h4 { color: var(--primary); font-size: 18px; margin-bottom: 8px; }
.timeline-item p { color: var(--text-light); }
.timeline-item .time-label {
  display: inline-block; background: var(--primary); color: #fff;
  padding: 4px 14px; border-radius: 20px; font-size: 13px; margin-bottom: 10px;
}

.stats-row {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(200px, 1fr));
  gap: 20px; margin: 30px 0;
}
.stat-box {
  background: linear-gradient(135deg, var(--card) 0%, #f7fafc 100%);
  border-radius: var(--radius); padding: 24px; text-align: center;
  box-shadow: var(--shadow); border-bottom: 3px solid var(--primary-light);
  transition: var(--transition);
}
.stat-box:nth-child(2) { border-bottom-color: var(--accent); }
.stat-box:nth-child(3) { border-bottom-color: var(--warm); }
.stat-box:nth-child(4) { border-bottom-color: var(--warm-dark); }
.stat-box:hover { transform: translateY(-4px); box-shadow: var(--shadow-hover); }
.stat-box .stat-num {
  font-size: 36px; font-weight: 800;
  background: linear-gradient(135deg, var(--primary), var(--accent));
  -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text;
}
.stat-box .stat-label { color: var(--text-light); font-size: 14px; margin-top: 6px; }

.carepedia-cta {
  background: linear-gradient(135deg, #1A73E8, #00C9A7);
  padding: 48px 24px; text-align: center; color: #fff;
}
.carepedia-cta h3 { font-size: 24px; font-weight: 700; margin-bottom: 12px; }
.carepedia-cta p { font-size: 16px; opacity: 0.9; margin-bottom: 24px; max-width: 500px; margin-left: auto; margin-right: auto; }
.carepedia-cta .cta-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 14px 32px; background: #fff; color: #1A73E8;
  text-decoration: none; border-radius: 30px; font-size: 16px; font-weight: 700;
  font-family: inherit; transition: all 0.3s ease; box-shadow: 0 4px 16px rgba(0,0,0,0.15);
}
.carepedia-cta .cta-btn:hover { transform: translateY(-2px); box-shadow: 0 8px 24px rgba(0,0,0,0.2); }

.credit-bar {
  display: flex; align-items: center; justify-content: center; gap: 16px; flex-wrap: wrap;
  padding: 14px 20px; font-size: 14px; color: rgba(255,255,255,0.85); position: relative; z-index: 1;
}
.credit-bar span { opacity: 0.9; }
.portal-request-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 10px 22px; background: var(--primary-light); color: #fff;
  text-decoration: none; border-radius: 30px; font-size: 14px;
  font-family: inherit; font-weight: 600; transition: var(--transition);
  box-shadow: 0 2px 12px rgba(0,0,0,0.15);
}
.portal-request-btn:hover { background: var(--primary); transform: translateY(-2px); box-shadow: 0 4px 20px rgba(0,0,0,0.2); }

.footer {
  background: var(--primary); color: rgba(255,255,255,0.8);
  text-align: center; padding: 40px; font-size: 14px;
}

.scroll-top {
  position: fixed; bottom: 30px; left: 30px;
  width: 50px; height: 50px; background: var(--primary);
  color: #fff; border: none; border-radius: 50%;
  font-size: 22px; cursor: pointer; box-shadow: var(--shadow);
  transition: var(--transition); opacity: 0; pointer-events: none; z-index: 999;
}
.scroll-top.visible { opacity: 1; pointer-events: auto; }
.scroll-top:hover { background: var(--primary-light); transform: translateY(-3px); }

.search-box { position: relative; margin: 0 auto; }
.search-box input {
  width: 100%; padding: 14px 20px 14px 50px;
  border: 2px solid rgba(15,76,117,0.15); border-radius: 30px;
  font-size: 16px; font-family: 'Rubik', sans-serif;
  background: var(--card); color: var(--text); transition: var(--transition);
  box-sizing: border-box;
}
.search-box input:focus { outline: none; border-color: var(--primary-light); box-shadow: 0 0 0 4px rgba(50,130,184,0.1); }
.search-box .search-icon {
  position: absolute; left: 18px; top: 50%;
  transform: translateY(-50%); font-size: 20px; pointer-events: none;
}

.sidebar-overlay {
  display: none; position: fixed; top: 0; left: 0; right: 0; bottom: 0;
  background: rgba(0,0,0,0.5); z-index: 999; opacity: 0; transition: opacity 0.3s ease;
}
.sidebar-overlay.active { display: block; opacity: 1; }

@media (max-width: 900px) {
  .sidebar { transform: translateX(-100%); width: 270px; }
  .sidebar.open { transform: translateX(0); }
  .menu-toggle { display: block; }
  .main { margin-left: 0; }
  .hero { padding: 60px 30px; }
  .section { padding: 40px 24px; }
}

@media (max-width: 768px) {
  .sidebar { transform: translateX(-100%); width: 260px; }
  .sidebar.open { transform: translateX(0); }
  .menu-toggle { display: block; }
  .main { margin-left: 0; }
  .hero { padding: 40px 20px 36px; }
  .hero h1 { font-size: 28px; line-height: 1.3; }
  .hero .greeting { font-size: 16px; line-height: 1.7; }
  .hero .subtitle { font-size: 14px; }
  .section { padding: 28px 16px; }
  .section-header { flex-direction: column; align-items: flex-start; gap: 8px; margin-bottom: 24px; padding-bottom: 14px; }
  .section-header .sec-icon { font-size: 32px; }
  .section-header h2 { font-size: 24px; }
  .section-header p { font-size: 14px; }
  .cards-grid { grid-template-columns: 1fr; gap: 16px; margin-bottom: 24px; }
  .card { padding: 20px; }
  .card:hover { transform: none; }
  .cat-card:hover { transform: none; }
  .stat-box:hover { transform: none; }
  .link-btn:hover { transform: none; }
  .portal-request-btn:hover { transform: none; }
  .scroll-top:hover { transform: none; }
  .sidebar nav a:hover { transform: none; }
  .card .card-icon { font-size: 32px; margin-bottom: 10px; }
  .card h3 { font-size: 17px; }
  .card p { font-size: 14px; }
  .cat-grid { grid-template-columns: repeat(2, 1fr); gap: 12px; margin-top: 24px; }
  .cat-card { padding: 18px 12px; }
  .cat-card .cat-icon { font-size: 32px; margin-bottom: 8px; }
  .cat-card h3 { font-size: 14px; }
  .cat-card p { font-size: 11px; }
  .stats-row { grid-template-columns: repeat(2, 1fr); gap: 12px; margin: 20px 0; }
  .stat-box { padding: 16px 10px; }
  .stat-box .stat-num { font-size: 26px; }
  .stat-box .stat-label { font-size: 12px; }
  .tabs { gap: 6px; margin-bottom: 16px; }
  .tab-btn { padding: 8px 14px; font-size: 13px; border-radius: 20px; }
  .styled-table { display: block; overflow-x: auto; -webkit-overflow-scrolling: touch; font-size: 13px; }
  .styled-table th { padding: 10px 12px; font-size: 13px; white-space: nowrap; }
  .styled-table td { padding: 10px 12px; font-size: 13px; min-width: 100px; }
  .info-box { padding: 16px 18px; margin: 16px 0; }
  .info-box h4 { font-size: 15px; }
  .info-box p { font-size: 13px; }
  .accordion-header { padding: 14px 16px; font-size: 15px; }
  .accordion-body .inner { padding: 14px 16px 18px; font-size: 14px; line-height: 1.9; }
  .timeline { padding-left: 30px; margin: 20px 0; }
  .timeline-item { padding: 16px; margin-bottom: 20px; }
  .timeline-item::before { left: -24px; width: 12px; height: 12px; top: 22px; }
  .timeline-item h4 { font-size: 16px; }
  .timeline-item p { font-size: 13px; }
  .link-btn { padding: 10px 16px; font-size: 13px; margin: 4px 2px; }
  .search-box input { padding: 12px 18px 12px 40px; font-size: 14px; }
  .footer { padding: 28px 16px; font-size: 13px; }
  .scroll-top { width: 42px; height: 42px; font-size: 18px; bottom: 20px; left: 16px; }
}

@media (max-width: 380px) {
  .hero h1 { font-size: 24px; }
  .hero .greeting { font-size: 15px; }
  .cat-grid { grid-template-columns: 1fr 1fr; gap: 8px; }
  .cat-card { padding: 14px 8px; }
  .cat-card .cat-icon { font-size: 26px; }
  .cat-card h3 { font-size: 13px; }
  .cat-card p { display: none; }
  .stats-row { grid-template-columns: 1fr 1fr; gap: 8px; }
  .stat-box .stat-num { font-size: 22px; }
  .section { padding: 20px 12px; }
  .tab-btn { padding: 7px 10px; font-size: 12px; }
}

.disclaimer-banner {
  background: linear-gradient(135deg, #FFF3E0, #FFF8E1);
  border-bottom: 2px solid #FFB74D;
  padding: 10px 20px; text-align: center; font-size: 13px; color: #5D4037;
  position: relative; z-index: 1500;
  display: flex; align-items: center; justify-content: center; gap: 8px; flex-wrap: wrap;
}
.disclaimer-banner strong { color: #E65100; }
.disclaimer-banner a { color: #1A73E8; text-decoration: underline; font-weight: 600; }
.disclaimer-banner a:hover { color: #0D47A1; }
@media (max-width: 768px) { .disclaimer-banner { font-size: 12px; padding: 8px 12px; } }
</style>
<script src="https://code.iconify.design/iconify-icon/2.1.0/iconify-icon.min.js" defer></script>
</head>
<body>

<!-- DISCLAIMER BANNER -->
<div class="disclaimer-banner">
  <iconify-icon icon="solar:danger-bold" style="font-size:16px;color:var(--forest);"></iconify-icon>
  <span><strong>This is not medical advice.</strong> Always consult your doctor. <a href="/disclaimer">Full legal disclaimer &rarr;</a></span>
</div>

<!-- SCROLL PROGRESS BAR -->
<div class="scroll-progress"><div class="bar" id="progressBar"></div></div>

<!-- MOBILE OVERLAY -->
<div class="sidebar-overlay" id="sidebarOverlay" onclick="closeMenu()"></div>

<!-- MOBILE MENU TOGGLE -->
<button class="menu-toggle" id="menuToggle" onclick="toggleMenu()"><iconify-icon icon="solar:hamburger-menu-bold"></iconify-icon></button>

<!-- SIDEBAR -->
<aside class="sidebar" id="sidebar">
  <div class="logo">
    <div class="icon"><iconify-icon icon="solar:drop-bold-duotone" style="font-size:44px;color:var(--amber);display:block;"></iconify-icon></div>
    <h2>Hemophilia Hub</h2>
  </div>
  <nav>
    <a href="#home" class="active" onclick="navigate(this)"><iconify-icon icon="solar:home-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Home</a>
    <a href="#about" onclick="navigate(this)"><iconify-icon icon="solar:book-2-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>What is Hemophilia?</a>
    <a href="#treatments" onclick="navigate(this)"><iconify-icon icon="solar:pill-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Treatments &amp; Medications</a>
    <a href="#trials" onclick="navigate(this)"><iconify-icon icon="solar:magnifier-zoom-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Clinical Trials</a>
    <a href="#research" onclick="navigate(this)"><iconify-icon icon="solar:dna-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>New Research</a>
    <a href="#children" onclick="navigate(this)"><iconify-icon icon="solar:users-group-two-rounded-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Children &amp; Hemophilia</a>
    <a href="#lifestyle" onclick="navigate(this)"><iconify-icon icon="solar:health-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Healthy Lifestyle</a>
    <a href="#physio" onclick="navigate(this)"><iconify-icon icon="solar:dumbbell-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Physiotherapy &amp; Sport</a>
    <a href="#women" onclick="navigate(this)"><iconify-icon icon="solar:heart-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Women &amp; Hemophilia</a>
    <a href="#emergency" onclick="navigate(this)"><iconify-icon icon="solar:alarm-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Emergency Protocol</a>
    <a href="#psychological-approach" onclick="navigate(this)"><iconify-icon icon="solar:brain-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Psychological Approach</a>
    <a href="#stories" onclick="navigate(this)"><iconify-icon icon="solar:star-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Success Stories</a>
    <a href="#resources" onclick="navigate(this)"><iconify-icon icon="solar:link-bold" class="nav-icon" style="font-size:20px;"></iconify-icon>Links &amp; Resources</a>
  </nav>
</aside>

<!-- MAIN CONTENT -->
<div class="main">

  <!-- HERO -->
  <section class="hero" id="home">
    <div class="credit-bar">
      <span>Built by <strong>Yuval Kashtker</strong> and his robot assistants</span>
      <a href="https://carepedia.org/en/#contact" target="_blank" class="portal-request-btn">
        ‚ûï Want a portal for another disease?
      </a>
    </div>
    <div class="hero-content">
      <h1>Hemophilia Information Center</h1>
      <p class="greeting">
        One place with in-depth information, up-to-date research, and practical tools<br>
        for people living with hemophilia and their families.
      </p>
      <p class="subtitle">
        Dramatic progress is being made in treatment. Gene therapy, innovative medications, and modern prophylaxis are transforming lives. Here you will find research-based information.
      </p>
      <div class="search-box" style="margin-top: 30px; max-width: 600px;">
        <span class="search-icon"><iconify-icon icon="solar:magnifier-bold" style="font-size:18px;color:rgba(255,255,255,0.6);"></iconify-icon></span>
        <input type="text" id="portalSearch" placeholder="Search the portal..." oninput="searchPortal(this.value)">
      </div>
      <div id="searchResults" style="display:none; margin-top: 16px; max-width: 600px;"></div>
    </div>
  </section>

  <!-- QUICK NAVIGATION -->
  <section class="section fade-in" style="padding-bottom: 20px;">
    <div class="cat-grid">
      <a class="cat-card" href="#about" onclick="navigateTo('about')">
        <div class="cat-icon"><iconify-icon icon="solar:book-2-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>What is Hemophilia?</h3>
        <p>Basic understanding of the disease</p>
      </a>
      <a class="cat-card" href="#treatments" onclick="navigateTo('treatments')">
        <div class="cat-icon"><iconify-icon icon="solar:pill-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Treatments &amp; Medications</h3>
        <p>Approved medications and new treatments</p>
      </a>
      <a class="cat-card" href="#trials" onclick="navigateTo('trials')">
        <div class="cat-icon"><iconify-icon icon="solar:magnifier-zoom-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Clinical Trials</h3>
        <p>Active research worldwide</p>
      </a>
      <a class="cat-card" href="#research" onclick="navigateTo('research')">
        <div class="cat-icon"><iconify-icon icon="solar:dna-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>New Research</h3>
        <p>Breakthroughs and latest discoveries</p>
      </a>
      <a class="cat-card" href="#children" onclick="navigateTo('children')">
        <div class="cat-icon"><iconify-icon icon="solar:users-group-two-rounded-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Children &amp; Hemophilia</h3>
        <p>Guide for parents and families</p>
      </a>
      <a class="cat-card" href="#lifestyle" onclick="navigateTo('lifestyle')">
        <div class="cat-icon"><iconify-icon icon="solar:health-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Healthy Lifestyle</h3>
        <p>Nutrition, sport and daily tips</p>
      </a>
      <a class="cat-card" href="#physio" onclick="navigateTo('physio')">
        <div class="cat-icon"><iconify-icon icon="solar:dumbbell-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Physiotherapy &amp; Sport</h3>
        <p>Joint preservation and physical activity</p>
      </a>
      <a class="cat-card" href="#women" onclick="navigateTo('women')">
        <div class="cat-icon"><iconify-icon icon="solar:heart-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Women &amp; Hemophilia</h3>
        <p>Carriers, symptoms and pregnancy</p>
      </a>
      <a class="cat-card" href="#emergency" onclick="navigateTo('emergency')">
        <div class="cat-icon"><iconify-icon icon="solar:alarm-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Emergency Protocol</h3>
        <p>What to do in an emergency</p>
      </a>
      <a class="cat-card" href="#psychological-approach" onclick="navigateTo('psychological-approach')">
        <div class="cat-icon"><iconify-icon icon="solar:brain-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Psychological Approach</h3>
        <p>Mental health and emotional coping</p>
      </a>
      <a class="cat-card" href="#stories" onclick="navigateTo('stories')">
        <div class="cat-icon"><iconify-icon icon="solar:star-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Success Stories</h3>
        <p>People living full lives</p>
      </a>
      <a class="cat-card" href="#resources" onclick="navigateTo('resources')">
        <div class="cat-icon"><iconify-icon icon="solar:link-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></div>
        <h3>Links &amp; Resources</h3>
        <p>Websites, organizations and tools</p>
      </a>
    </div>
  </section>

  <!-- SECTION: ABOUT HEMOPHILIA -->
  <section class="section fade-in" id="about">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:book-2-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>What is Hemophilia?</h2>
        <p>Basic understanding of the disease, types and symptoms</p>
      </div>
    </div>

    <div class="stats-row">
      <div class="stat-box">
        <div class="stat-num">1.2M+</div>
        <div class="stat-label">People living with hemophilia worldwide</div>
      </div>
      <div class="stat-box">
        <div class="stat-num">400,000+</div>
        <div class="stat-label">With severe hemophilia A</div>
      </div>
      <div class="stat-box">
        <div class="stat-num">80-85%</div>
        <div class="stat-label">Of cases are hemophilia A</div>
      </div>
      <div class="stat-box">
        <div class="stat-num">30+</div>
        <div class="stat-label">Countries with national hemophilia programs</div>
      </div>
    </div>

    <div class="info-box">
      <h4>What happens in the body?</h4>
      <p>Hemophilia is an inherited bleeding disorder in which the blood does not clot properly due to a deficiency of specific clotting factors. In hemophilia A, factor VIII is missing; in hemophilia B, factor IX is missing. The genes for both factors are located on the X chromosome, so the condition primarily affects males. Women are typically carriers, though some experience symptoms. Hemophilia C (factor XI deficiency) is also known and affects both sexes via autosomal recessive inheritance.</p>
    </div>

    <h3 style="font-size: 24px; color: var(--primary); margin: 30px 0 20px;">Types of Hemophilia</h3>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">üÖ∞Ô∏è</div>
        <h3>Hemophilia A (Classic)</h3>
        <p>Factor VIII deficiency. Accounts for 80‚Äì85% of cases. Severity is determined by factor level: mild (5‚Äì40%), moderate (1‚Äì5%), severe (below 1%).</p>
      </div>
      <div class="card green">
        <div class="card-icon">üÖ±Ô∏è</div>
        <h3>Hemophilia B (Christmas Disease)</h3>
        <p>Factor IX deficiency. Accounts for 15‚Äì20% of cases. Treatment is similar but uses a different factor. Alprolix and Idelvion allow injections once per week or once every two weeks.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">üÜé</div>
        <h3>Hemophilia C (Rosenthal Disease)</h3>
        <p>Factor XI deficiency. Autosomal recessive inheritance, affects both sexes. Generally milder than A and B. More common in certain populations including Ashkenazi Jewish individuals.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">‚ö†Ô∏è</div>
        <h3>Acquired Hemophilia</h3>
        <p>Not inherited. Caused by autoantibodies against factor VIII. Rare: 1‚Äì4 per million per year. More common in older adults. Requires specialized treatment.</p>
      </div>
    </div>

    <h3 style="font-size: 24px; color: var(--primary); margin: 30px 0 20px;">Main Symptoms</h3>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">ü©∏</div>
        <h3>Joint Bleeds (Hemarthrosis)</h3>
        <p>Repeated bleeding mainly in the knees, elbows and ankles. Causes pain, swelling, local warmth and cumulative joint damage (hemophilic arthropathy).</p>
      </div>
      <div class="card green">
        <div class="card-icon">üí™</div>
        <h3>Muscle Bleeds</h3>
        <p>Deep bleeding into muscles that can compress nerves and blood vessels. A bleed in the iliopsoas muscle (abdomen/hip) is a medical emergency.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">üî¥</div>
        <h3>Excessive Bruising</h3>
        <p>Large and frequent bruises, sometimes without an obvious cause. One of the first signs in young children.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">ü¶∑</div>
        <h3>Prolonged Bleeding</h3>
        <p>Bleeding that does not stop after cuts, surgeries, dental extractions or injuries. Also spontaneous internal bleeding in severe hemophilia.</p>
      </div>
    </div>

    <div class="info-box success">
      <h4>The Good News</h4>
      <p>In recent decades there has been a dramatic revolution in hemophilia treatment. Life expectancy has risen from around 30 years in the 1960s to near-normal today. Preventive therapy (prophylaxis) prevents up to 95% of spontaneous bleeds. In 2022‚Äì2024, gene therapies were approved that promise fundamental change: Hemgenix for hemophilia B and Roctavian for hemophilia A.</p>
    </div>

    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>How is hemophilia diagnosed?</span>
        <span class="arrow">‚ñº</span>
      </div>
      <div class="accordion-body">
        <div class="inner">
          <p>Blood tests: PT (normal), aPTT (prolonged), specific factor levels (VIII, IX, XI). Genetic testing to identify the exact mutation and for carrier detection. Prenatal diagnosis is possible at week 11‚Äì14 (chorionic villus sampling) or week 15‚Äì20 (amniocentesis). PGD (pre-implantation genetic diagnosis) is also available. Genetic testing for carriers with a family history is recommended and widely available through specialist centers.</p>
        </div>
      </div>
    </div>
  </section>

  <!-- SECTION: TREATMENTS -->
  <section class="section fade-in" id="treatments">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:pill-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Treatments &amp; Medications</h2>
        <p>Key medications, innovative therapies, and what to ask your doctor</p>
      </div>
    </div>

    <div class="info-box">
      <h4>The Principle of Treatment</h4>
      <p>The cornerstone of hemophilia management is prevention (prophylaxis), not just treating bleeds. Large studies have proven that regular preventive therapy reduces bleeds by 95%, prevents joint damage, and significantly improves quality of life. The World Health Organization (WHO), World Federation of Hemophilia (WFH) and ISTH all recommend prophylaxis as the standard of care.</p>
    </div>

    <!-- Tabs for treatments -->
    <div class="tabs" data-tab-group="treatments">
      <button class="tab-btn active" data-tab="main-meds" onclick="switchTab('treatments','main-meds')">Main Medications</button>
      <button class="tab-btn" data-tab="new-treatments" onclick="switchTab('treatments','new-treatments')">Innovative Therapies</button>
      <button class="tab-btn" data-tab="inhibitors" onclick="switchTab('treatments','inhibitors')">Inhibitors</button>
      <button class="tab-btn" data-tab="ask-doctor" onclick="switchTab('treatments','ask-doctor')">Questions for Your Doctor</button>
    </div>

    <!-- Tab: Main Medications -->
    <div class="tab-content active" data-tab-content="treatments" data-tab="main-meds">
      <table class="styled-table">
        <thead>
          <tr><th>Medication</th><th>Type</th><th>What it does</th><th>Notes</th></tr>
        </thead>
        <tbody>
          <tr>
            <td><strong>Recombinant Factor VIII</strong><br>(Advate, Kovaltry, Eloctate)</td>
            <td>Factor replacement</td>
            <td>Replaces the missing factor in hemophilia A</td>
            <td>Standard treatment. IV injection 2‚Äì3 times per week. Eloctate has an extended half-life.</td>
          </tr>
          <tr>
            <td><strong>Recombinant Factor IX</strong><br>(BeneFIX, Alprolix, Idelvion)</td>
            <td>Factor replacement</td>
            <td>Replaces the missing factor in hemophilia B</td>
            <td>Alprolix and Idelvion: injection once per week to once every two weeks only.</td>
          </tr>
          <tr>
            <td><strong>Emicizumab</strong><br>(Hemlibra)</td>
            <td>Bispecific antibody</td>
            <td>Mimics the action of factor VIII. Revolutionary: subcutaneous injection.</td>
            <td>Approved in 2017. Reduces bleeds by 87%. Suitable for patients with inhibitors too.</td>
          </tr>
          <tr>
            <td><strong>DDAVP</strong><br>(Desmopressin)</td>
            <td>Factor releaser</td>
            <td>Releases stored factor VIII from natural body reserves</td>
            <td>Effective for mild hemophilia A only. Given by injection, infusion or nasal spray.</td>
          </tr>
          <tr>
            <td><strong>Tranexamic Acid</strong><br>(Cyklokapron)</td>
            <td>Antifibrinolytic</td>
            <td>Prevents breakdown of an existing clot</td>
            <td>Excellent for oral bleeding and after dental procedures. Available as tablets or mouthwash.</td>
          </tr>
        </tbody>
      </table>
    </div>

    <!-- Tab: New Treatments -->
    <div class="tab-content" data-tab-content="treatments" data-tab="new-treatments">
      <div class="cards-grid">
        <div class="card green">
          <div class="card-icon"><iconify-icon icon="solar:dna-bold" style="font-size:36px;color:var(--forest);"></iconify-icon></div>
          <h3>Gene Therapy: Hemgenix</h3>
          <p>FDA-approved in November 2022 for hemophilia B. An AAV5 vector delivers a functional copy of the FIX gene to the liver. In the HOPE-B study: 94% of patients stopped routine prophylaxis. FIX levels rose to an average of 36.2% and remained stable even 3 years after a single treatment. Price: approximately $3.5 million for a one-time infusion.</p>
        </div>
        <div class="card orange">
          <div class="card-icon"><iconify-icon icon="solar:dna-bold" style="font-size:36px;color:var(--forest);"></iconify-icon></div>
          <h3>Gene Therapy: Roctavian</h3>
          <p>Approved by the EMA in 2022 and the FDA in 2023 for severe hemophilia A. AAV5 vector carrying a truncated FVIII gene. 87% of patients stopped prophylaxis in the first year. Note: FVIII levels decline gradually over time. Long-term follow-up is required.</p>
        </div>
        <div class="card">
          <div class="card-icon">üíâ</div>
          <h3>Fitusiran ‚Äî Alhemo</h3>
          <p>An antibody against antithrombin. Subcutaneous injection once per month only. Reduces bleeds by 90%+. Suitable for hemophilia A and B, with or without inhibitors. Approved in Europe and Japan; FDA approval process ongoing.</p>
        </div>
        <div class="card">
          <div class="card-icon"><iconify-icon icon="solar:magnifier-zoom-bold" style="font-size:36px;color:var(--forest);"></iconify-icon></div>
          <h3>Concizumab</h3>
          <p>An antibody against TFPI (Tissue Factor Pathway Inhibitor). Daily subcutaneous injection. Bleed reduction of 85%+. In advanced approval stages (Phase 3: explorer7, explorer8).</p>
        </div>
        <div class="card blue">
          <div class="card-icon">üéØ</div>
          <h3>Mim8 ‚Äî Novo Nordisk</h3>
          <p>A next-generation bispecific antibody (next generation after Emicizumab). Promising Phase 3 results (FRONTIER). Subcutaneous injection once per week or once per month. Expected FDA submission in 2025‚Äì2026.</p>
        </div>
      </div>
    </div>

    <!-- Tab: Inhibitors -->
    <div class="tab-content" data-tab-content="treatments" data-tab="inhibitors">
      <div class="info-box warning">
        <h4>The Biggest Challenge</h4>
        <p>About 30% of patients with severe hemophilia A and 3‚Äì5% of those with hemophilia B develop inhibitors (antibodies against the injected factor). This is the greatest challenge in hemophilia treatment today.</p>
      </div>

      <div class="cards-grid" style="margin-top: 20px;">
        <div class="card">
          <h3>Bypassing Agents</h3>
          <p>FEIBA (aPCC) and NovoSeven (rFVIIa). These bypass the need for factor VIII/IX. Effective in 80‚Äì90% of bleeding episodes. Used for acute treatment and prevention.</p>
        </div>
        <div class="card green">
          <h3>ITI ‚Äî Immune Tolerance Induction</h3>
          <p>Frequent high-dose factor injections over months to years. The goal: to "teach" the immune system to accept the factor. Success rate: 60‚Äì80% in hemophilia A. Expensive and complex but worth the investment.</p>
        </div>
        <div class="card orange">
          <h3>Emicizumab for Inhibitors</h3>
          <p>Completely changed treatment for patients with inhibitors. Not affected by antibodies because it works through a different pathway. Reduced bleeds by 87% in the HAVEN 1 study (NEJM 2017).</p>
        </div>
      </div>
    </div>

    <!-- Tab: Ask Doctor -->
    <div class="tab-content" data-tab-content="treatments" data-tab="ask-doctor">
      <div class="cards-grid" style="margin-top: 20px;">
        <div class="card">
          <h3>Questions About Prophylaxis</h3>
          <ul style="padding-left: 16px; color: var(--text-light);">
            <li>Am I receiving optimal prophylaxis?</li>
            <li>Is there a treatment with less frequent injections?</li>
            <li>What about Emicizumab?</li>
            <li>Am I a candidate for gene therapy?</li>
          </ul>
        </div>
        <div class="card green">
          <h3>Questions About Inhibitors</h3>
          <ul style="padding-left: 16px; color: var(--text-light);">
            <li>What is the likelihood that I will develop inhibitors?</li>
            <li>What tests need to be done?</li>
            <li>When should ITI be considered?</li>
            <li>Is Emicizumab suitable for me?</li>
          </ul>
        </div>
        <div class="card orange">
          <h3>Questions About Joints</h3>
          <ul style="padding-left: 16px; color: var(--text-light);">
            <li>What is the condition of my joints (MRI/ultrasound)?</li>
            <li>Is there early joint damage starting?</li>
            <li>What physiotherapy is recommended?</li>
            <li>When should orthopaedic surgery be considered?</li>
          </ul>
        </div>
      </div>
    </div>
  </section>

  <!-- SECTION: CLINICAL TRIALS -->
  <section class="section fade-in" id="trials">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:magnifier-zoom-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Clinical Trials</h2>
        <p>Active research worldwide ‚Äî participation opportunities</p>
      </div>
    </div>

    <div class="info-box">
      <h4>Clinical Trials in Hemophilia</h4>
      <p>Over 300 active clinical trials in hemophilia are ongoing worldwide. Participating in a trial can offer access to cutting-edge therapies before they are widely available. Every trial is reviewed by an ethics committee, includes close medical monitoring, and contributes to research that benefits everyone.</p>
    </div>

    <div class="timeline">
      <div class="timeline-item">
        <div class="time-label">Gene Therapy</div>
        <h4>Hemgenix: Long-Term Follow-Up</h4>
        <p>The HOPE-B study continues to follow hemophilia B patients who received gene therapy. Three-year data: FIX levels stable, 94% stopped prophylaxis. CSL Behring is continuing long-term monitoring.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Gene Therapy</div>
        <h4>Roctavian: Follow-Up and Expansion</h4>
        <p>BioMarin continues follow-up of hemophilia A patients. A key question: how long does the effect last? Data show gradual decline in FVIII levels in some patients.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Gene Therapy</div>
        <h4>Pfizer: giroctocogene fitelparvovec</h4>
        <p>Phase 3 trial for hemophilia A. A different approach: AAV6 vector instead of AAV5. Early results are promising. FDA submission expected in 2025.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Non-Factor</div>
        <h4>Fitusiran: ATLAS Program</h4>
        <p>Multiple Phase 3 trials (ATLAS-A/B/INH/PPX). Subcutaneous injection once per month. Results: over 90% bleed reduction. Sanofi advancing regulatory approval.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Non-Factor</div>
        <h4>Concizumab: explorer Program</h4>
        <p>Novo Nordisk: Phase 3 trials (explorer7, explorer8). Anti-TFPI antibody. Bleed reduction 85%+. Daily subcutaneous injection.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Non-Factor</div>
        <h4>Mim8: FRONTIER Program</h4>
        <p>Novo Nordisk: next-generation bispecific antibody. Phase 3. Weekly or monthly subcutaneous injection. Excellent early results.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Global</div>
        <h4>Find a Trial Near You</h4>
        <p>The WFH Clinical Trials Registry and ClinicalTrials.gov list all active hemophilia trials globally. Contact your local hemophilia treatment center to find out which trials you may be eligible for.</p>
      </div>
    </div>

    <div style="margin-top: 12px;">
      <a href="https://clinicaltrials.gov/search?cond=Hemophilia&status=RECRUITING" target="_blank" class="link-btn">ClinicalTrials.gov ‚Äî Hemophilia</a>
      <a href="https://clinicaltrials.wfh.org/" target="_blank" class="link-btn green">WFH Clinical Trials Registry</a>
    </div>
  </section>

  <!-- SECTION: RESEARCH -->
  <section class="section fade-in" id="research">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:dna-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>New Research</h2>
        <p>Breakthroughs and latest discoveries in hemophilia</p>
      </div>
    </div>

    <div class="info-box success">
      <h4>A New Era in Hemophilia (2022‚Äì2025)</h4>
      <p>2022‚Äì2025 represent revolutionary years in hemophilia. Gene therapy, new non-factor medications, and advanced monitoring technologies are changing the face of the disease. Here are the most significant breakthroughs.</p>
    </div>

    <div class="cards-grid">
      <div class="card green">
        <div class="card-icon"><iconify-icon icon="solar:dna-bold" style="font-size:36px;color:var(--forest);"></iconify-icon></div>
        <h3>Gene Therapy: The Next Generation</h3>
        <p>After the approvals of Hemgenix and Roctavian, researchers are focused on improvements: more efficient vectors, lower doses, longer-lasting effect. Spark Therapeutics is working on SPK-8011 combined with immunosuppression. The potential for a genuine cure for the disease is now real.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">üíâ</div>
        <h3>The Non-Factor Therapy Revolution</h3>
        <p>Emicizumab changed the rules in 2017. Now Fitusiran, Concizumab and Mim8 are expanding the options. All are subcutaneous injections; all are suitable for patients with inhibitors as well. The future: personalized therapy tailored to each patient.</p>
      </div>
      <div class="card">
        <div class="card-icon"><iconify-icon icon="solar:magnifier-zoom-bold" style="font-size:36px;color:var(--forest);"></iconify-icon></div>
        <h3>Joint Health: MRI Studies</h3>
        <p>New MRI studies show that early prophylaxis prevents joint damage almost entirely. HEAD2HEAD study (2024): comparison of Emicizumab with factor VIII shows a small advantage for Emicizumab in joint protection.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">üéØ</div>
        <h3>Personalized Treatment (PK-Guided)</h3>
        <p>Pharmacokinetic (PK) models allow factor dosing to be calibrated individually for each patient. Apps like myPKFiT predict factor levels at any moment. Result: fewer injections, greater protection.</p>
      </div>
      <div class="card">
        <div class="card-icon">üìä</div>
        <h3>New Biomarkers</h3>
        <p>Researchers are developing tools to predict bleeds before they happen. Markers of joint inflammation, new coagulation markers, and digital monitoring enable early intervention and damage prevention.</p>
      </div>
    </div>
  </section>

  <!-- SECTION: CHILDREN -->
  <section class="section fade-in" id="children">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:users-group-two-rounded-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Children &amp; Hemophilia</h2>
        <p>A guide for parents and families</p>
      </div>
    </div>

    <div class="info-box">
      <h4>Hemophilia in Childhood</h4>
      <p>Most severe hemophilia cases are diagnosed in the first year of life. Early diagnosis and preventive treatment allow children to grow and develop like any other child. Here is what is important to know.</p>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">üçº</div>
        <h3>Early Diagnosis</h3>
        <p>Most severe cases are diagnosed in the first year: unexplained bruising, prolonged bleeding after circumcision, joint bleeds when crawling begins. A simple blood test (aPTT + factor level) confirms the diagnosis. Newborn testing is recommended for families with a known history.</p>
      </div>
      <div class="card green">
        <div class="card-icon">üè´</div>
        <h3>School and Play</h3>
        <p>It is important to inform the educational team. Prepare a written emergency action plan. Most physical activities are permitted: swimming, running, cycling, basketball. Avoid full-contact sports (boxing, rugby). Do not wrap the child in cotton wool.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">üíâ</div>
        <h3>Self-Treatment</h3>
        <p>From age 8‚Äì12, children can begin learning to self-infuse intravenously. A gradual process: watching, assisting, supervised infusion, independent infusion. Improves independence, confidence and quality of life. Hemophilia treatment centers offer professional training.</p>
      </div>
      <div class="card">
        <div class="card-icon">üß∏</div>
        <h3>Emotional Support</h3>
        <p>Children with hemophilia may experience frustration, fear and isolation. Psychological support is important. Support groups for children and special summer camps (organized by WFH and NHF) are very helpful. Talk to your child openly about the condition.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">ü¶∑</div>
        <h3>Dental Care</h3>
        <p>Aggressive preventive maintenance: brushing with fluoride toothpaste, dental floss, visits every 6 months. Before any invasive procedure: coordinate with the hematologist. Tranexamic acid around procedures. Hospital dental clinics are familiar with hemophilia.</p>
      </div>
      <div class="card green">
        <div class="card-icon">üéí</div>
        <h3>Transition to Adulthood</h3>
        <p>Transition clinics from age 16‚Äì18. Gradual transfer of responsibility from parents to the adolescent. Introduction to the adult hemophilia clinic. Topics include family planning, genetic counseling, and career choice. WFH offers dedicated transition programs.</p>
      </div>
    </div>
  </section>

  <!-- SECTION: LIFESTYLE -->
  <section class="section fade-in" id="lifestyle">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:health-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Healthy Lifestyle</h2>
        <p>Nutrition, sport and daily tips</p>
      </div>
    </div>

    <div class="info-box">
      <h4>Living Fully with Hemophilia</h4>
      <p>Living with hemophilia does not mean giving things up. With proper preventive treatment and planning, you can travel, work, play sport and live a full life. Here is what is worth knowing.</p>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">ü•ó</div>
        <h3>Nutrition</h3>
        <p>Maintaining a healthy weight is important for joint protection. Vitamin D and calcium to prevent osteoporosis (common in hemophilia). Iron if bleeds are frequent. Avoid high-dose omega-3 supplements (may affect clotting). A Mediterranean diet is recommended.</p>
      </div>
      <div class="card green">
        <div class="card-icon">üö¥</div>
        <h3>Physical Activity</h3>
        <p>Swimming, walking, cycling, Pilates and yoga are excellent. Strengthen muscles around joints. Avoid full-contact sport (boxing, rugby, ice hockey). Always coordinate with your hematologist and physiotherapist. Regular physical activity actually reduces bleeds.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">ü¶∑</div>
        <h3>Dental Care</h3>
        <p>Thorough daily dental cleaning. Visits every 6 months. Coordinate with the hematologist before any invasive procedure. Tranexamic acid before and after procedures. Prefer dental clinics at hospitals familiar with hemophilia.</p>
      </div>
      <div class="card">
        <div class="card-icon">‚úàÔ∏è</div>
        <h3>Travel</h3>
        <p>Carry double the usual medication supply. A medical letter in English from the hematologist. List of hemophilia centers at your destination (WFH Global Treatment Centre Directory). Travel insurance covering pre-existing conditions. Keep medications in carry-on luggage (not checked baggage).</p>
      </div>
      <div class="card blue">
        <div class="card-icon">üÜò</div>
        <h3>Emergency Preparedness</h3>
        <p>Always wear a medical identification bracelet or necklace. An emergency kit at home and in the car (medication, emergency numbers, medical letter). Treatment center emergency numbers saved on your phone. The HemMobile app for tracking bleeds and infusions.</p>
      </div>
      <div class="card green">
        <div class="card-icon">üíä</div>
        <h3>Medications to Avoid</h3>
        <p>Aspirin and NSAIDs (such as ibuprofen, diclofenac) increase bleeding. Paracetamol (acetaminophen) is safe. Always inform every doctor and pharmacist that you have hemophilia. Be careful with herbal products that affect clotting (ginkgo, garlic, ginseng).</p>
      </div>
    </div>
  </section>

  <!-- SECTION: PHYSIO -->
  <section class="section fade-in" id="physio">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:dumbbell-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Physiotherapy &amp; Sport</h2>
        <p>Joint preservation and physical activity</p>
      </div>
    </div>

    <div class="info-box">
      <h4>Physical Activity as Part of Treatment</h4>
      <p>Regular physical activity is a critical part of hemophilia management. Strong muscles protect joints, reduce bleeds, and improve quality of life. Studies from 2024 showed that a tailored physiotherapy program reduces joint bleeds by 40%.</p>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">üèä</div>
        <h3>Swimming and Hydrotherapy</h3>
        <p>The most recommended activity for hemophilia. Zero load on joints. Strengthens muscles. Suitable even after a joint bleed and during rehabilitation. Souza et al., 2024: swimming improved range of motion by 30% in hemophilia patients.</p>
      </div>
      <div class="card green">
        <div class="card-icon">üö¥</div>
        <h3>Cycling</h3>
        <p>Low joint load. Strengthens the legs. A stationary bike is preferable (safer than outdoor cycling). 30 minutes, 3 times per week. Strengthens thigh muscles that protect the knees.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">üßò</div>
        <h3>Yoga and Pilates</h3>
        <p>Improves flexibility, strength and coordination. Reduces chronic pain. Strengthens the core. Cakmak et al., 2022: yoga improved quality of life by 40% in hemophilia patients. Choose an instructor who knows how to make adaptations.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">üèãÔ∏è</div>
        <h3>Strength Training</h3>
        <p>Strengthening muscles around vulnerable joints is critical. Light to moderate weights, 2‚Äì3 sets of 12‚Äì15 repetitions. Physiotherapist guidance is essential at the start. Avoid very heavy weights and explosive movements.</p>
      </div>
    </div>

    <div class="info-box warning">
      <h4>Sports to Avoid</h4>
      <p>Full-contact sports (boxing, karate, rugby, ice hockey), sports with a high fall risk (skiing, skateboarding, horse riding), very heavy weightlifting. Always consult with your hematologist and physiotherapist before starting a new activity.</p>
    </div>

    <div class="info-box success">
      <h4>Tip: WFH Sport Risk Categories</h4>
      <p>The WFH recommends Risk Categories for sport. Category 1 (safe): swimming, walking, cycling. Category 2 (moderate): basketball, football, tennis. Category 3 (high risk): boxing, rugby, ice hockey. Choose from Category 1‚Äì2 and ensure adequate prophylaxis.</p>
    </div>
  </section>

  <!-- SECTION: WOMEN -->
  <section class="section fade-in" id="women">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:heart-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Women &amp; Hemophilia</h2>
        <p>Carriers, symptoms, pregnancy and childbirth</p>
      </div>
    </div>

    <div class="info-box">
      <h4>Not Only Men</h4>
      <p>Hemophilia does not only affect men. Female carriers can suffer from significant symptoms, and approximately 30% of carriers experience increased bleeding. It is important for carrier women to have their factor levels checked.</p>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon"><iconify-icon icon="solar:dna-bold" style="font-size:36px;color:var(--forest);"></iconify-icon></div>
        <h3>Carriers</h3>
        <p>Women with a mutation in the F8 or F9 gene on one X chromosome. Factor levels can range from 10‚Äì100% (due to random X-inactivation). Genetic testing is recommended for families with a known history. Specialist hemophilia centers provide carrier testing and counseling.</p>
      </div>
      <div class="card green">
        <div class="card-icon">ü©∏</div>
        <h3>Heavy Menstrual Bleeding</h3>
        <p>About 60% of carriers suffer from heavy menstrual bleeding (menorrhagia). Treatments: tranexamic acid, hormonal contraceptives, levonorgestrel intrauterine device (IUD), DDAVP. Anyone with heavy periods and a family history of hemophilia should be evaluated.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">ü§∞</div>
        <h3>Pregnancy and Childbirth</h3>
        <p>Pregnancy in a hemophilia carrier requires close monitoring by a hematologist, obstetrician and anesthesiologist. Factor VIII levels naturally rise during pregnancy (partial protection), but FIX levels do not. Epidural analgesia is possible only if factor levels are above 50%. Advance planning of delivery is essential.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">üë∂</div>
        <h3>Prenatal Diagnosis</h3>
        <p>Chorionic villus sampling (CVS) at weeks 11‚Äì14, amniocentesis at weeks 15‚Äì20. PGD (pre-implantation genetic diagnosis) allows selection of embryos without the mutation. NIPT (non-invasive prenatal testing) can determine fetal sex. Genetic testing options are available through specialist centers worldwide.</p>
      </div>
    </div>
  </section>

  <!-- SECTION: EMERGENCY -->
  <section class="section fade-in" id="emergency">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:alarm-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Emergency Protocol</h2>
        <p>What to do in a bleeding emergency</p>
      </div>
    </div>

    <div class="info-box warning">
      <h4>The Rule: Treat First, Ask Questions Later</h4>
      <p>Active bleeding in hemophilia requires prompt treatment. When in doubt, give factor. An intracranial bleed is the number one cause of death in hemophilia and requires immediate factor replacement plus emergency care.</p>
    </div>

    <div class="cards-grid">
      <div class="card" style="border-top-color: #E63946; border-top-width: 5px;">
        <div class="card-icon">üß†</div>
        <h3>Intracranial Bleed (Absolute Emergency)</h3>
        <p>Signs: sudden severe headache, vomiting, confusion, loss of consciousness, one-sided weakness. Action: give factor immediately ‚Äî do not wait for tests. Go to the emergency room immediately. Even a head injury without symptoms requires immediate factor replacement and 24-hour monitoring.</p>
      </div>
      <div class="card green">
        <div class="card-icon">ü¶µ</div>
        <h3>Joint Bleed</h3>
        <p>Signs: pain, swelling, local warmth, difficulty moving. Action: RICE (Rest, Ice 15 minutes, Compression with an elastic bandage, Elevation) + factor replacement. If this is a first bleed in a new joint: see a doctor within 24 hours.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">üí™</div>
        <h3>Muscle Bleed</h3>
        <p>Signs: deep pain, swelling, difficulty moving. Iliopsoas bleed (abdominal/hip muscle): abdominal or hip pain, difficulty straightening the leg. This is an emergency. Action: factor replacement + rest. Physiotherapy only after the bleed has stopped.</p>
      </div>
      <div class="card">
        <div class="card-icon">ü©∏</div>
        <h3>External Bleeding That Won't Stop</h3>
        <p>Direct continuous pressure on the wound for 15‚Äì20 minutes (do not lift the dressing to check). If it does not stop: factor replacement + emergency room. Tranexamic acid for oral bleeding.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">ü¶∑</div>
        <h3>After Dental Treatment</h3>
        <p>Tranexamic acid 3 times daily for 5‚Äì7 days. Soft, cold food for the first 48 hours. Do not rinse the mouth forcefully. If bleeding recurs: tranexamic acid + factor replacement.</p>
      </div>
    </div>

    <h3 style="margin: 40px 0 20px; color: var(--primary); font-size: 22px;">When to Go to the Emergency Room</h3>
    <table class="styled-table">
      <thead>
        <tr><th>Situation</th><th>Action</th></tr>
      </thead>
      <tbody>
        <tr><td>Sudden severe headache + vomiting</td><td><strong>Immediate emergency room + factor</strong></td></tr>
        <tr><td>Bleeding that does not stop after 20 minutes of pressure</td><td><strong>Emergency room</strong></td></tr>
        <tr><td>Neck/throat bleed (risk of airway obstruction)</td><td><strong>Immediate emergency room + factor</strong></td></tr>
        <tr><td>Abdominal bleed (pain + swelling)</td><td><strong>Emergency room + factor</strong></td></tr>
        <tr><td>Head injury (even without symptoms)</td><td><strong>Immediate factor + 24-hour monitoring</strong></td></tr>
        <tr><td>Eye bleed (pain + vision change)</td><td><strong>Emergency room + factor</strong></td></tr>
        <tr><td>Blood in urine or stool</td><td><strong>Contact doctor the same day</strong></td></tr>
      </tbody>
    </table>
  </section>

  <!-- SECTION: PSYCHOLOGICAL APPROACH -->
  <section class="section fade-in" id="psychological-approach">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:brain-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Psychological Approach</h2>
        <p>Mental health, emotional coping and living with hemophilia</p>
      </div>
    </div>

    <div class="info-box">
      <h4>The Mind is Part of Treatment</h4>
      <p>Current research shows that more than 40% of people with hemophilia experience symptoms of depression, and 55% report anxiety (Frontiers in Public Health, 2024). World Federation of Hemophilia (WFH) guidelines establish that psychological support is an inseparable part of comprehensive multidisciplinary care. Mental health is not a "bonus" ‚Äî it is an essential component of disease management.</p>
    </div>

    <h3 style="font-size: 24px; color: var(--primary); margin: 30px 0 20px;">Key Psychological Challenges</h3>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">üò∞</div>
        <h3>Fear of Bleeding and Activity Avoidance</h3>
        <p>84% of patients report avoiding physical activity, and 73.7% have difficulty participating in sport and hobbies. Fear of bleeding creates a negative cycle: avoidance of activity leads to muscle weakness, which increases vulnerability to bleeds. This phenomenon is called kinesiophobia (fear of movement) and is documented in many studies. Breaking the cycle requires combined professional support from a psychologist and physiotherapist.</p>
      </div>
      <div class="card green">
        <div class="card-icon">üíî</div>
        <h3>Chronic Pain and Psychological Impact</h3>
        <p>40‚Äì70% of people with hemophilia suffer from chronic pain resulting from hemophilic arthropathy (cumulative joint damage). The American PFiQ study found that 62% reported current pain and 85% had experienced pain in the previous four weeks. Pain, depression and anxiety form a self-reinforcing cycle: pain intensifies depression, depression reduces coping with pain, and anxiety amplifies the perception of pain.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">ü´•</div>
        <h3>Stigma and Social Isolation</h3>
        <p>Many patients conceal their diagnosis out of fear of rejection and stigma. Misconceptions persist, including confusion that hemophilia is contagious. Children are particularly affected and struggle to build close friendships. A 2025 study (Frontiers in Psychiatry) documents that stigma damages interpersonal relationships and leads to social isolation. Recommended interventions include structured family education, peer-led support groups, and awareness-raising among medical teams.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">üö´</div>
        <h3>Psychological Barriers to Treatment Adherence</h3>
        <p>57% of patients aged 25‚Äì40 struggle with adherence to prophylaxis. Psychological barriers include: denial (especially common in adolescence), fear of needles, inaccurate health beliefs, depression that reduces motivation, and lifestyle conflicts. Depression, anxiety and pain each independently predict lower treatment adherence.</p>
      </div>
    </div>

    <h3 style="font-size: 24px; color: var(--primary); margin: 30px 0 20px;">By Age: Unique Challenges</h3>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">üë∂</div>
        <h3>Children: Fear of Needles and Restrictions</h3>
        <p>Fear of needles is a major source of distress in children with hemophilia. Anxiety causes vein constriction, making infusion harder and creating a negative cycle. Evidence-based approaches: medical play with real equipment on dolls, topical anesthetic cream (EMLA), the Buzzy device (vibration and cooling), distraction techniques (bubbles, screens, games), gradual exposure from watching to self-injection, and giving the child a sense of control (choice of arm, position, timing). Beyond injections, children also cope with activity restrictions, feeling different from peers, and school difficulties.</p>
      </div>
      <div class="card green">
        <div class="card-icon">üßë‚Äçüéì</div>
        <h3>Adolescents: Transition, Identity and Self-Management</h3>
        <p>Adolescence is particularly challenging. Self-infusion begins on average at age 12.3, but full self-management is achieved only at an average age of 22.6. Treatment adherence during adolescence is at its lowest, leading to repeated bleeds and cumulative damage. Disease denial is a common mechanism at this age. Adolescents also navigate decisions about disclosure (whom to tell), building a social identity, peer pressure, and the transition from pediatric to adult care. Telehealth education has shown significant improvement in transition readiness and self-efficacy.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">üë®‚Äçüë©‚Äçüëß‚Äçüë¶</div>
        <h3>Parents and Caregivers: Emotional Burden</h3>
        <p>65.4% of parents report an emotional impact from hemophilia, and 92.3% feel financial strain. Mothers sometimes experience guilt (because the condition is transmitted through the X chromosome). The central conflict: wanting the child to grow up normally versus the need to protect against bleeds. "Healthy" siblings may be pushed to the margins when care demands dominate family life. Parents lose an average of 8.35 work days per year. It is important for parents to also receive psychological support, not only the child.</p>
      </div>
    </div>

    <div class="info-box success">
      <h4>The Good News: There Are Tools That Work</h4>
      <p>Studies show that psychological interventions in hemophilia are effective. Cognitive Behavioral Therapy (CBT), mindfulness, support groups and empowerment programs have been proven to improve quality of life, emotional regulation and coping with pain. You do not have to cope alone.</p>
    </div>

    <h3 style="font-size: 24px; color: var(--primary); margin: 30px 0 20px;">Evidence-Based Tools and Interventions</h3>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">üß©</div>
        <h3>Cognitive Behavioral Therapy (CBT)</h3>
        <p>CBT has been specifically proven effective in hemophilia for improving emotional regulation and quality of life (Cochrane, 2020). Combining CBT with physiotherapy simultaneously reduced chronic pain and kinesiophobia. Therapy helps halt negative thoughts ("the bleed will never stop"), manage anger, and cope better in social situations. Recommended for any patient dealing with chronic pain, anxiety or depression.</p>
      </div>
      <div class="card green">
        <div class="card-icon">üßò</div>
        <h3>Mindfulness and Pain Management</h3>
        <p>A multimodal approach to pain management is the professional standard (expert recommendations, PMC 2021). Beyond medication, recommendations include: Mindfulness-Based Stress Reduction (MBSR), guided imagery, biofeedback, hypnosis, hydrotherapy, and electrical stimulation (TENS). The combined approach includes: clotting factor treatment, analgesic medication, physiotherapy, psychological therapy, and complementary treatments such as acupuncture.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">ü§ù</div>
        <h3>Support Groups and Community</h3>
        <p>Meeting others living with the same condition reduces isolation and provides a sense of belonging. Organizations such as the WFH and NHF run support groups for patients and families, summer camps for children, events and meetups, and assistance with accessing equipment and services. Online communities and telehealth programs offer additional access. The WFH also facilitates global peer support networks.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">üè•</div>
        <h3>International Resources</h3>
        <p>Major hemophilia treatment centers worldwide operate multidisciplinary teams including psychologists and social workers. Contact your nearest World Federation of Hemophilia (WFH) member organization for local support resources. The NHF (National Hemophilia Foundation) and European Haemophilia Consortium (EHC) also maintain directories of patient support services. Do not hesitate to ask for help ‚Äî seeking support is a sign of strength, not weakness.</p>
      </div>
    </div>

    <div class="info-box warning">
      <h4>When to Seek Professional Help</h4>
      <p>If you are experiencing persistent sadness, changes in sleep or appetite, withdrawal from social activities, avoidance of treatment, or feelings of hopelessness, contact your hemophilia treatment center team. Teams include psychologists and social workers familiar with the unique challenges of living with hemophilia. You are not alone.</p>
    </div>
  </section>

  <!-- SECTION: STORIES -->
  <section class="section fade-in" id="stories">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:star-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Success Stories</h2>
        <p>People living full lives with hemophilia</p>
      </div>
    </div>

    <div class="info-box success">
      <h4>Full Lives with Hemophilia</h4>
      <p>Today, a child born with hemophilia in a country with access to modern treatment can expect a long, active and full life. Modern preventive therapy enables sport, work, travel and family life. Here are some inspiring examples.</p>
    </div>

    <div class="cards-grid">
      <div class="card green" style="border-top-width: 6px;">
        <div class="card-icon">üö¥</div>
        <h3>Alex Dowsett</h3>
        <p>British professional cyclist with severe hemophilia A. He broke the world hour record in 2015 (52.937 km). He proved that even with hemophilia it is possible to reach the pinnacle of sport. Founder of the Little Bleeders charity for children with hemophilia.</p>
      </div>
      <div class="card orange" style="border-top-width: 6px;">
        <div class="card-icon">üèÉ</div>
        <h3>Ryan White</h3>
        <p>Born with hemophilia in 1971. He contracted HIV from contaminated blood products. He became a symbol of the fight against stigma and changed US legislation (Ryan White CARE Act 1990). His story transformed blood product safety forever.</p>
      </div>
      <div class="card blue" style="border-top-width: 6px;">
        <div class="card-icon">üåç</div>
        <h3>The Global Community</h3>
        <p>The World Federation of Hemophilia and national member organizations run activities, summer camps and family meetups worldwide. Over 1.2 million people with hemophilia globally benefit from advancing science and an expanding network of hemophilia treatment centers.</p>
      </div>
      <div class="card" style="border-top-width: 6px;">
        <div class="card-icon">üé¨</div>
        <h3>The Disease That Changed Blood Medicine</h3>
        <p>Thanks to the hemophilia community, enormous advances have been made in blood medicine: recombinant technology, blood product safety, gene therapy. Achievements that are transforming the lives of millions of people with various bleeding disorders around the world.</p>
      </div>
    </div>
  </section>

  <!-- SECTION: RESOURCES -->
  <section class="section fade-in" id="resources">
    <div class="section-header">
      <span class="sec-icon"><iconify-icon icon="solar:link-bold" style="font-size:40px;color:var(--forest);"></iconify-icon></span>
      <div>
        <h2>Links &amp; Resources</h2>
        <p>Websites, organizations, tools and useful apps</p>
      </div>
    </div>

    <h3 style="color: var(--primary); margin-bottom: 20px;">Leading Organizations</h3>
    <div class="cards-grid">
      <div class="card green">
        <h3>World Federation of Hemophilia (WFH)</h3>
        <p>The leading international organization. Information, guidelines, global treatment centre directory.</p>
        <a href="https://wfh.org" target="_blank" class="link-btn green" style="margin-top: 10px;">wfh.org</a>
      </div>
      <div class="card blue">
        <h3>National Hemophilia Foundation (NHF)</h3>
        <p>The US organization. Comprehensive information, research, community and advocacy.</p>
        <a href="https://www.hemophilia.org" target="_blank" class="link-btn" style="margin-top: 10px;">hemophilia.org</a>
      </div>
      <div class="card orange">
        <h3>European Haemophilia Consortium (EHC)</h3>
        <p>The European organization. Guidelines, advocacy and research.</p>
        <a href="https://www.ehc.eu" target="_blank" class="link-btn orange" style="margin-top: 10px;">ehc.eu</a>
      </div>
      <div class="card">
        <h3>Hemophilia Federation of America</h3>
        <p>Patient advocacy, education, and community resources for people with bleeding disorders in the United States.</p>
        <a href="https://www.hemophiliafed.org" target="_blank" class="link-btn" style="margin-top: 10px;">hemophiliafed.org</a>
      </div>
    </div>

    <h3 style="color: var(--primary); margin: 40px 0 20px;">Major Treatment Centers Worldwide</h3>
    <div class="cards-grid">
      <div class="card green">
        <h3>WFH Global Treatment Centre Directory</h3>
        <p>The WFH maintains a comprehensive directory of hemophilia treatment centers in over 130 countries. Use it to find an accredited center near you or when traveling.</p>
        <a href="https://www.wfh.org/en/page.aspx?pid=643" target="_blank" class="link-btn green" style="margin-top: 10px;">Find a Center</a>
      </div>
      <div class="card blue">
        <h3>US Hemophilia Treatment Centers</h3>
        <p>The US has over 140 federally funded hemophilia treatment centers providing comprehensive multidisciplinary care. Managed by the American Thrombosis and Hemostasis Network (ATHN).</p>
        <a href="https://www.athn.org/htc-directory.html" target="_blank" class="link-btn" style="margin-top: 10px;">ATHN HTC Directory</a>
      </div>
      <div class="card orange">
        <h3>European Centers of Expertise</h3>
        <p>The European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet) coordinates hemophilia care across Europe.</p>
        <a href="https://eurobloodnet.eu/" target="_blank" class="link-btn orange" style="margin-top: 10px;">ERN-EuroBloodNet</a>
      </div>
      <div class="card">
        <h3>Pediatric Hemophilia Centers</h3>
        <p>Many comprehensive hemophilia treatment centers have dedicated pediatric programs. Ask your national hemophilia organization for the nearest center with a specialist pediatric team.</p>
      </div>
    </div>

    <h3 style="color: var(--primary); margin: 40px 0 20px;">Recommended Apps</h3>
    <table class="styled-table">
      <thead><tr><th>App</th><th>What it does</th><th>Cost</th></tr></thead>
      <tbody>
        <tr><td><strong>HemMobile</strong></td><td>Track bleeds, infusions and medications</td><td>Free</td></tr>
        <tr><td><strong>myPKFiT</strong></td><td>Personal factor level prediction</td><td>Free</td></tr>
        <tr><td><strong>Haemophilia Physio</strong></td><td>Physiotherapy exercises tailored to hemophilia</td><td>Free</td></tr>
        <tr><td><strong>HemDiary</strong></td><td>Bleed diary and joint monitoring</td><td>Free</td></tr>
      </tbody>
    </table>

    <h3 style="color: var(--primary); margin: 40px 0 20px;">Key Research Articles (Citations)</h3>
    <div class="cards-grid">
      <div class="card">
        <h3>Gene Therapy</h3>
        <ul style="padding-left: 16px; font-size: 14px; color: var(--text-light);">
          <li>Pipe et al. (2023) NEJM: Hemgenix 3-year follow-up</li>
          <li>Mahlangu et al. (2023) NEJM: Roctavian Phase 3</li>
          <li>Ozelo et al. (2022) NEJM: Hemgenix HOPE-B results</li>
        </ul>
      </div>
      <div class="card green">
        <h3>Non-Factor Therapies</h3>
        <ul style="padding-left: 16px; font-size: 14px; color: var(--text-light);">
          <li>Oldenburg et al. (2017) NEJM: Emicizumab HAVEN 1</li>
          <li>Young et al. (2023): Fitusiran ATLAS results</li>
          <li>Shapiro et al. (2023): Concizumab explorer5</li>
        </ul>
      </div>
      <div class="card orange">
        <h3>Guidelines and Reviews</h3>
        <ul style="padding-left: 16px; font-size: 14px; color: var(--text-light);">
          <li>Srivastava et al. (2020): WFH Guidelines 3rd edition</li>
          <li>Mannucci (2020) Haematologica: 50 years of treatment</li>
          <li>Manco-Johnson et al. (2007) NEJM: Joint Outcome Study</li>
        </ul>
      </div>
    </div>

    <h3 style="color: var(--primary); margin: 40px 0 20px;">Recommended Books</h3>
    <div class="cards-grid">
      <div class="card">
        <h3>Raising a Child with Hemophilia</h3>
        <p>Laurie Kelley. A comprehensive guide for parents. Covers all aspects: treatment, school, sport, emotion.</p>
      </div>
      <div class="card green">
        <h3>My Blood Doesn't Clot</h3>
        <p>A children's book that explains hemophilia in simple language. Excellent for children aged 4‚Äì8.</p>
      </div>
      <div class="card orange">
        <h3>Guidelines for the Management of Hemophilia</h3>
        <p>WFH, 2020. The official guidelines. Free to download from the WFH website.</p>
        <a href="https://doi.org/10.1111/hae.14046" target="_blank" class="link-btn orange" style="margin-top: 10px;">Download</a>
      </div>
    </div>
  </section>

  <!-- FOOTER -->
  <footer class="footer">
    <p style="margin-bottom: 16px;">
      Built by <strong>Yuval Kashtker</strong> and his robot assistants
    </p>
    <a href="https://carepedia.org/en/#contact" target="_blank" class="portal-request-btn" style="margin-bottom: 20px;">‚ûï Want a portal for another disease?</a>
    <p style="margin-top: 20px; font-size: 15px; opacity: 0.85;">All information on this site is for educational purposes only and does not constitute a substitute for professional medical advice.</p>
    <p style="margin-top: 8px; font-size: 13px; opacity: 0.7;"><a href="/disclaimer" style="color:var(--accent-light);text-decoration:underline;">Legal Disclaimer</a> | <a href="https://wa.me/+972526414555" target="_blank" rel="noopener" style="color:var(--accent-light);text-decoration:underline;">Report an Error</a></p>
    <p style="margin-top: 10px; font-size: 14px; opacity: 0.7;">Last updated: February 2026 | Includes citations from peer-reviewed articles</p>
  </footer>

</div>

<!-- SCROLL TO TOP -->
<button class="scroll-top" id="scrollTop" onclick="window.scrollTo({top:0,behavior:'smooth'})"><iconify-icon icon="solar:arrow-up-bold"></iconify-icon></button>

<script>
function toggleMenu() {
  const sidebar = document.getElementById('sidebar');
  const toggle = document.getElementById('menuToggle');
  const overlay = document.getElementById('sidebarOverlay');
  sidebar.classList.toggle('open');
  toggle.classList.toggle('open');
  overlay.classList.toggle('active');
  document.body.style.overflow = sidebar.classList.contains('open') ? 'hidden' : '';
}

function closeMenu() {
  const sidebar = document.getElementById('sidebar');
  const toggle = document.getElementById('menuToggle');
  const overlay = document.getElementById('sidebarOverlay');
  sidebar.classList.remove('open');
  toggle.classList.remove('open');
  overlay.classList.remove('active');
  document.body.style.overflow = '';
}

function navigate(el) {
  document.querySelectorAll('.sidebar nav a').forEach(a => a.classList.remove('active'));
  el.classList.add('active');
  closeMenu();
}

function navigateTo(id) {
  const el = document.getElementById(id);
  if (el) el.scrollIntoView({ behavior: 'smooth' });
  document.querySelectorAll('.sidebar nav a').forEach(a => {
    a.classList.toggle('active', a.getAttribute('href') === '#' + id);
  });
}

function toggleAccordion(header) {
  const body = header.nextElementSibling;
  const isOpen = header.classList.contains('open');
  header.classList.toggle('open');
  body.style.maxHeight = isOpen ? '0' : body.scrollHeight + 'px';
}

function switchTab(tabGroup, tabName) {
  document.querySelectorAll('[data-tab-group="' + tabGroup + '"] .tab-btn').forEach(b => {
    b.classList.toggle('active', b.dataset.tab === tabName);
  });
  document.querySelectorAll('[data-tab-content="' + tabGroup + '"]').forEach(c => {
    c.classList.toggle('active', c.dataset.tab === tabName);
  });
}

// Scroll progress bar
window.addEventListener('scroll', () => {
  const scrollTop = document.getElementById('scrollTop');
  const progressBar = document.getElementById('progressBar');
  const scrolled = window.scrollY;
  const maxScroll = document.documentElement.scrollHeight - window.innerHeight;
  const pct = maxScroll > 0 ? (scrolled / maxScroll) * 100 : 0;
  progressBar.style.width = pct + '%';
  scrollTop.classList.toggle('visible', scrolled > 500);

  // Scroll spy
  const sections = document.querySelectorAll('.section[id], .hero[id]');
  let current = '';
  sections.forEach(s => {
    if (scrolled >= s.offsetTop - 100) current = s.id;
  });
  if (current) {
    document.querySelectorAll('.sidebar nav a').forEach(a => {
      a.classList.toggle('active', a.getAttribute('href') === '#' + current);
    });
  }
});

// Fade-in on scroll (IntersectionObserver)
const fadeEls = document.querySelectorAll('.fade-in');
const observer = new IntersectionObserver((entries) => {
  entries.forEach(entry => {
    if (entry.isIntersecting) {
      entry.target.classList.add('visible');
    }
  });
}, { threshold: 0.1, rootMargin: '0px 0px -50px 0px' });
fadeEls.forEach(el => observer.observe(el));

// Portal search
function searchPortal(query) {
  const resultsDiv = document.getElementById('searchResults');
  if (!query || query.length < 2) {
    resultsDiv.style.display = 'none';
    document.querySelectorAll('.section').forEach(s => s.style.display = '');
    return;
  }
  const q = query.toLowerCase();
  const sections = document.querySelectorAll('.section[id]');
  const matches = [];
  sections.forEach(s => {
    const text = s.textContent.toLowerCase();
    const title = s.querySelector('h2') ? s.querySelector('h2').textContent : '';
    if (text.includes(q)) {
      matches.push({ id: s.id, title: title, el: s });
      s.style.display = '';
    } else {
      s.style.display = 'none';
    }
  });
  if (matches.length > 0 && matches.length < sections.length) {
    resultsDiv.innerHTML = '<div style="background:var(--card);border-radius:var(--radius);padding:16px 20px;box-shadow:var(--shadow);">' +
      '<p style="font-size:14px;color:var(--text-light);margin-bottom:8px;">' + matches.length + ' results found:</p>' +
      matches.map(m => '<a href="#' + m.id + '" onclick="navigateTo(\'' + m.id + '\')" style="display:block;padding:8px 12px;color:var(--primary);text-decoration:none;border-radius:8px;font-weight:600;transition:var(--transition);" onmouseover="this.style.background=\'var(--bg)\'" onmouseout="this.style.background=\'transparent\'">' + m.title + '</a>').join('') +
      '</div>';
    resultsDiv.style.display = 'block';
  } else if (matches.length === sections.length) {
    resultsDiv.style.display = 'none';
  } else {
    resultsDiv.innerHTML = '<div style="background:var(--card);border-radius:var(--radius);padding:16px 20px;box-shadow:var(--shadow);"><p style="font-size:14px;color:var(--text-light);">No results found. Try a different word.</p></div>';
    resultsDiv.style.display = 'block';
  }
}
</script>

</body>
</html>
